A Randomized, Double-blind, Placebo-controlled, Parallel-group Proof of Concept Study to Evaluate the Effect of AFQ056 in Obsessive Compulsive Disorder (OCD) Patients Resistant to Selective Serotonin Reuptake Inhibitor (SSRI) Therapy
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Mavoglurant (Primary) ; Serotonin uptake inhibitors
- Indications Obsessive-compulsive disorders
- Focus Proof of concept; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 02 Jan 2017 Primary endpoint of yale - brown obsessive compulsive scale (Y-BOCS) absolute change from baseline at week 17 has not been met, according to result published in the Advances in Therapy.
- 02 Jan 2017 Results of interim analysis (n=50) published in the Advances in Therapy
- 09 Jun 2016 Status changed from completed to discontinued at the time of the first Interim Analysis (IA) as the study did not meet its primary efficacy objective